{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:47:26Z","timestamp":1782175646782,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,22]]},"DOI":"10.7759\/cureus.111312","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:57:36Z","timestamp":1782172656000},"source":"Crossref","is-referenced-by-count":0,"title":["Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves"],"prefix":"10.7759","author":[{"given":"Oscar J","family":"Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Peruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimra","family":"Tul Ain Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragnan","family":"Kancharla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo C","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al.. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015, 33:2516-22. 10.1200\/JCO.2014.59.7534","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","volume":"184","author":"Link BK","year":"2019","unstructured":"Link BK, Day BM, Zhou X, et al.. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019, 184:660-3. 10.1111\/bjh.15149","journal-title":"Br J Haematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA- 5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson CA","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, et al.. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA- 5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022, 23:91-103. 10.1016\/S1470-2045(21)00591-X","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu SS","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, et al.. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024, 143:496-506. 10.1182\/blood.2023021243","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler NH","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, et al.. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022, 28:325-32. 10.1038\/s41591-021-01622-0","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling M","year":"2024","unstructured":"Dreyling M, Fowler NH, Dickinson M, et al.. Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update. Blood. 2024, 143:1713-25. 10.1182\/blood.2023021567","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser F","year":"2024","unstructured":"Morschhauser F, Dahiya S, Palomba ML, et al.. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024, 30:2199-207. 10.1038\/s41591-024-02986-9","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde LE","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, et al.. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022, 23:1055-65. 10.1016\/S1470-2045(22)00335-7","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn LH","year":"2025","unstructured":"Sehn LH, Bartlett NL, Matasar MJ, et al.. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies. Blood. 2025, 145:708-19. 10.1182\/blood.2024025454","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL- 1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton KM","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, et al.. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL- 1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024, 11:e593-605. 10.1016\/S2352-3026(24)00166-2","journal-title":"Lancet Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani PL","year":"2023","unstructured":"Zinzani PL, Mayer J, Flowers CR, et al.. ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol. 2023, 41:5107-17. 10.1200\/JCO.23.00775","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot P","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012, 12:9. 10.1186\/1471-2288-12-9","journal-title":"BMC Med Res Methodol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu N","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021, 21:111. 10.1186\/s12874-021-01308-8","journal-title":"BMC Med Res Methodol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston P","year":"2013","unstructured":"Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013, 13:152. 10.1186\/1471-2288-13-152","journal-title":"BMC Med Res Methodol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson BD","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014, 32:3059-68. 10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"ref16","unstructured":"The R project for statistical computing. (2023). Accessed. February 5, 2026: https:\/\/www.R-project.org\/."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee DW","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al.. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019, 25:625-38. 10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione P","year":"2023","unstructured":"Ghione P, Palomba ML, Ghesquieres H, et al.. Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 2023, 108:822-32. 10.3324\/haematol.2022.281421","journal-title":"Haematologica"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione P","year":"2022","unstructured":"Ghione P, Palomba ML, Patel AR, et al.. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma. Blood. 2022, 140:851-60. 10.1182\/blood.2021014375","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2289854","article-title":"Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r\/r follicular lymphoma","volume":"65","author":"Dickinson M","year":"2024","unstructured":"Dickinson M, Martinez-Lopez J, Jousseaume E, et al.. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r\/r follicular lymphoma. Leuk Lymphoma. 2024, 65:323-32. 10.1080\/10428194.2023.2289854","journal-title":"Leuk Lymphoma"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00610-1","article-title":"Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma","volume":"14","author":"Nastoupil LJ","year":"2025","unstructured":"Nastoupil LJ, Bonner A, Wang P, et al.. Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma. Exp Hematol Oncol. 2025, 14:30. 10.1186\/s40164-025-00610-1","journal-title":"Exp Hematol Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018, 38:200-11. 10.1177\/0272989X17725740","journal-title":"Med Decis Making"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/504718-durability-benchmarking-of-contemporary-second-line-and-later-therapies-for-relapsed-or-refractory-follicular-lymphoma-using-reconstructed-individual-patient-data-from-published-kaplan-meier-curves","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:57:37Z","timestamp":1782172657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/504718-durability-benchmarking-of-contemporary-second-line-and-later-therapies-for-relapsed-or-refractory-follicular-lymphoma-using-reconstructed-individual-patient-data-from-published-kaplan-meier-curves"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.111312","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}